This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Six New Plaintiffs Join Sanford Heisler's $100m Gender Discrimination Class Action Against Forest Laboratories & Forest Pharmaceuticals

Stocks in this article: FRX

In the news release, Six New Plaintiffs Join Sanford Heisler's $100m Gender Discrimination Class Action Against Forest Laboratories & Forest Pharmaceuticals, issued Nov. 5, 2012 by Sanford Heisler, LLP over PR Newswire, we are advised by the law firm that the dateline should read "NEW YORK" rather than "NEWARK, N.J." as originally issued inadvertently. The complete, corrected release follows:

Six New Plaintiffs Join Sanford Heisler's $100m Gender Discrimination Class Action Against Forest Laboratories & Forest Pharmaceuticals

Ten Former and Current Mothers and Pregnant Women Cite Egregious Conditions

NEW YORK, Nov. 5, 2012 /PRNewswire/ -- Sanford Heisler, LLP, today added six additional female plaintiffs to the $100 million gender discrimination employment class action complaint the firm initially filed in July against New York-based Forest Laboratories, Inc., and Forest Pharmaceuticals, Inc.

The amended complaint was filed in the federal court for the Southern District of New York this morning. It increases the number of named plaintiffs to ten and provides additional support to the assertion that Forest discriminates against its female employees from coast to coast.

"The amended complaint reflects the unfortunate reality that the first four named plaintiffs comprise just a fraction of the women subjected to gender discrimination at Forest Pharmaceuticals," said David Sanford, Chairman of Sanford Heisler LLP and lead attorney for the plaintiffs. "Information about the full extent of the hostile work environment that pregnant women and mothers endure companywide continues to emerge, as more and more women employed by this pharma giant find out that much of what they are subjected to as Forest employees is illegal. We expect this class to be quite large."

The new named plaintiffs – all of whom are current or former high-performing Forest sales representatives – are Los Angeles residents Kimberly Clinton and Maria Avila; York, PA, resident Erin Eckenrode; Lebanon, PA, resident Julie Smyth; Louisville, KY, resident Andrea Harley; and Girard, IL, resident Christy Louder. The four original plaintiffs are Pennsylvania resident Megan Barrett and Texas residents, Lindsey Houser, Jennifer Jones and Jennifer Seard.

All ten named plaintiffs are current or former sales representatives of Forest. "This case is very similar in many ways to the Novartis gender discrimination case we tried in the Southern District of New York in 2010 where, on behalf of the female sales reps, we won a $253 million jury verdict," said Mr. Sanford.

The original and amended complaints assert Forest's female sales representatives have been and continue to be paid less than similarly situated male employees, despite the women's exemplary work performance. As a result of their gender, all ten of the named plaintiffs were denied bonuses, promotions, stock options and other employment incentives to which they were entitled.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs